Heckel B (2024) Idiopathic intracranial hypertension after Abrupt Cessation of Medication: a Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) receptor Agonist Cessation and Review of the literature
Front Neurosci 9:111 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue
The first seven trials involved patients with T2DM and baseline glycated hemoglobin levels ranging from 7.3 to 8.7, whereas the most recent SELECT trial focused on nondiabetic patients with overweight or obesity and preexisting cardiovascular disease
Estas mejoras no buscan sustituir lo que falta, es mucho ms complejo, sostiene Morales, para acuar el trmino de multimodulacin de los receptores GLP-1 con el fin de explicar su efecto multiorgnico
Wellorithm GLP-1 Program Overview 2026: How the Platform Connects Patients With Licensed Clinicians and Compounded Options GLP-1 receptor agonist medications have become one of the most talked-about developments in weight management in recent years, and access to these medications through telehealth platforms has grown significantly heading into 2026
